122 related articles for article (PubMed ID: 34263282)
1. Biomarker barcodes: multiplexed microfluidic immunohistochemistry enables high-throughput analysis of tissue microarray.
Cho CH; Cho M; Park JK
Lab Chip; 2021 Sep; 21(18):3471-3482. PubMed ID: 34263282
[TBL] [Abstract][Full Text] [Related]
2. A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers.
Wu X; Zahari MS; Renuse S; Jacob HK; Sakamuri S; Singal M; Gabrielson E; Sukumar S; Pandey A
Cancer Biol Ther; 2014; 15(12):1593-9. PubMed ID: 25535895
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
[TBL] [Abstract][Full Text] [Related]
5. A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis.
Kwon S; Cho CH; Kwon Y; Lee ES; Park JK
Sci Rep; 2017 Apr; 7():45968. PubMed ID: 28378835
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform.
Kim MS; Kim T; Kong SY; Kwon S; Bae CY; Choi J; Kim CH; Lee ES; Park JK
PLoS One; 2010 May; 5(5):e10441. PubMed ID: 20454672
[TBL] [Abstract][Full Text] [Related]
7. Combining fluorescence-based image segmentation and automated microfluidics for ultrafast cell-by-cell assessment of biomarkers for HER2-type breast carcinoma.
Migliozzi D; Nguyen HT; Gijs MAM
J Biomed Opt; 2018 Nov; 24(2):1-8. PubMed ID: 30484294
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
Sandén E; Khazaei S; Tryggvadottir H; Borgquist S; Isaksson K; Jirström K; Jernström H
Virchows Arch; 2020 Aug; 477(2):317-320. PubMed ID: 32080761
[TBL] [Abstract][Full Text] [Related]
9. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
[TBL] [Abstract][Full Text] [Related]
10. Concordance of HER2 Immunohistochemistry and Fluorescence
Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
[TBL] [Abstract][Full Text] [Related]
11. Validation of tissue microarray biomarker expression of breast carcinomas in Saudi women.
Alkushi A
Hematol Oncol Stem Cell Ther; 2009; 2(3):394-8. PubMed ID: 20139052
[TBL] [Abstract][Full Text] [Related]
12. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer diagnostics using microfluidic multiplexed immunohistochemistry.
Kim MS; Kwon S; Park JK
Methods Mol Biol; 2013; 949():349-64. PubMed ID: 23329453
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
[TBL] [Abstract][Full Text] [Related]
16. Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ.
Quintayo MA; Starczynski J; Yan FJ; Wedad H; Nofech-Mozes S; Rakovitch E; Bartlett JM
Histopathology; 2014 Jul; 65(1):2-8. PubMed ID: 24267587
[TBL] [Abstract][Full Text] [Related]
17. Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer.
Shamai G; Binenbaum Y; Slossberg R; Duek I; Gil Z; Kimmel R
JAMA Netw Open; 2019 Jul; 2(7):e197700. PubMed ID: 31348505
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
[TBL] [Abstract][Full Text] [Related]
19. Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information system.
Laurinaviciene A; Plancoulaine B; Baltrusaityte I; Meskauskas R; Besusparis J; Lesciute-Krilaviciene D; Raudeliunas D; Iqbal Y; Herlin P; Laurinavicius A
Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S10. PubMed ID: 25565007
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray technology in breast cancer HER2 diagnostics.
Egervari K; Szollosi Z; Nemes Z
Pathol Res Pract; 2007; 203(3):169-77. PubMed ID: 17292562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
